Pharmacokinetics and pharmacodynamics of GSK961081, a novel inhaled muscarinic antagonist β2‐agonist, and fluticasone propionate administered alone, concurrently and as a combination blend formulation in healthy volunteers
Authors:
- 20 February 2014
- journal article
- research article
- Published by Wiley in Clinical Pharmacology in Drug Development
- Vol. 3 (4) , 305-313
Abstract
Objective: To investigate the pharmacokinetics and pharmacodynamics of inhaled GSK961081 and fluticasone propionate (FP) given alone, concurrently and as a combination blend formulation.Methods: The study was double‐blind, double‐dummy, four‐way crossover. Twenty‐four healthy volunteers took single doses of the following in randomized order: (1) GSK961081 800 µg; (2) FP 500 µg; (3) GSK961081 800 µg and FP 500 µg as a blend formulation; and (4) GSK961081 800 µg and FP 500 µg concurrently via separate inhalers. The eLung breathing simulator was also used for the in vitro characterization of the formulations.Results: There was no pharmacokinetic interaction when GSK961081 and FP were administered concurrently. Mean Cmax and AUC(0−t) of GSK961081 were lower (∼20%) and mean Cmax and AUC(0−t) of FP were higher (two fold) following GSK961081/FP blend formulation compared to concurrent or the individual components alone. There was an increase in the FP in vitro ex‐throat dose for the GSK961081/FP blend from the eLung breathing simulator. Serum cortisol suppression was greater with GSK961081/FP blend, with lower (∼10%) cortisol levels than after GSK961081 + FP concurrent or FP alone.Conclusion: GSK961081/FP blend formulation was associated with an increase in FP systemic exposure and greater serum cortisol suppression.Keywords
Funding Information
- GlaxoSmithKline
This publication has 22 references indexed in Scilit:
- A new class of bronchodilator improves lung function in COPD: a trial with GSK961081European Respiratory Journal, 2013
- THRX-198321 Is a Bifunctional Muscarinic Receptor Antagonist and β2-Adrenoceptor Agonist (MABA) That Binds in a Bimodal and Multivalent MannerMolecular Pharmacology, 2011
- The scientific rationale for combining long-acting β2-agonists and muscarinic antagonists in COPDPulmonary Pharmacology & Therapeutics, 2010
- The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trialRespiratory Research, 2009
- Studies of the Human Oropharyngeal Airspaces Using Magnetic Resonance Imaging IV—The Oropharyngeal Retention Effect for Four Inhalation Delivery SystemsJournal of Aerosol Medicine, 2007
- Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paperEuropean Respiratory Journal, 2004
- Next Generation Pharmaceutical Impactor (A New Impactor for Pharmaceutical Inhaler Testing). Part I: DesignJournal of Aerosol Medicine, 2003
- Single‐Dose and Steady‐State Pharmacokinetic and Pharmacodynamic Evaluation of Therapeutically Clinically Equivalent Doses of Inhaled Fluticasone Propionate and Budesonide, Given as Diskus® or Turbohaler® Dry‐Powder Inhalers to Healthy SubjectsThe Journal of Clinical Pharmacology, 2001
- Design, validation and initial testing of the Electronic LungTM deviceJournal of Aerosol Science, 1998
- The Characterisation of Inhalation Devices by an Inhalation Simulator: The Electronic Lung ™Journal of Aerosol Medicine, 1994